Mumbai, September 27, 2022 (GPN): Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader announced that its India operations has become a signatory of the United Nations Global Compact (UNGC), the largest sustainability initiative globally. …
An extended half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A, resulting in lower weekly infusion rates than standard FVIII, providing excellent prophylactic coverage · Adynovate in combination with MYPKFIT®offers personalized treatment and enables HCPs and…
MUMBAI, 9 MAY, 2022 (GPN): In November 2021, Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, together with UNGCNI launched a national initiative for improving early access to treatment for Rare Disease Patients in India….
Takeda was recognized for its holistic initiatives designed to improve the quality of life and standards of care for patients The company recently pioneered the ‘Blueprint for rare diseases’ initiative designed for multi-stakeholder engagement and collaboration…
